A similar mechanism is often present in prostate cancer, where the TMPRSS2::ERG oncofusion is found in roughly 50% of tumors and MAN2A1::FER, MTOR::TP52BP1, and SLC45A2::AMACR occur at lower frequencies. Here, TMPRSS2 is linked to prostate carcinoma.